Pall — Q2 2015 Earnings Presentation
20 slides from Pall's earnings presentation, Feb 24, 2015
Slide 1: Q2 FY 2015 Financial Results
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2015 Pall Corporation Q2 FY 2015 Financi
Slide 2: Forward-Looking Statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the second quarter of fiscal year 2015 are preliminary until our Form 10-Q is filed with the Securities and Exchange Commission on or befo
Slide 3: Conference Call Information
3 Conference Call Information Dial-In: Toll-Free 855.356.7268 International 706.634.1981 Replay: Toll-Free 855.859.2056 International 404.537.3406 Conference ID: 81570552 Internet: www.pall.com/investor Pall Micro-24 Gas Micro Mixer enables precision control of oxygen and carbon dioxide in m
Slide 4: Q2 Overview
4 Q2 Overview Solid quarter – Modest growth – Continued operating margin improvement – Exceptional cash flow Similar end-market dynamics Translational FX headwinds – Current rates are a significant headwind to our original FY15 guidance assumptions Solid execution in the face of significant FX
Slide 5: Q2 Financial Summary
5 $677 $674 $- $200 $400 $600 $800 Revenue % Growth Excluding FX FY 2014 FY 2015 Q2 Financial Summary Dollars in millions, except EPS data A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix. 18.2% 18.5% 10.0% 15.0% 20. % Operat
Slide 6: Q2 Sales by Segment
6 Life Sciences Consumables $329 +11% Industrial Consumables $261 +2% Industrial Systems $54 +9% Life Sciences Systems $30 -6% 39% 49% 8% 4% Q2 Sales by Segment Dollars in millions Percentages outside pie charts and in box represent sales change excluding FX Percentages inside pie charts represent p
Slide 7: Q2 Life Sciences Segment Performance
7 Q2 Life Sciences Segment Performance Dollars in millions Life Sciences markets’ consumables sales growth percentages are excluding FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix 0% 30% 60% 54.9% -170 bps 56.6% 0% 30% 6
Slide 8: Q2 Industrial Segment Performance
8 Q2 Industrial Segment Performance Gross Margin Segment Margin Process Technologies consumables: Flat Aerospace consumables: +8% Microelectronics consumables: +3% 0% 30% 60% 45.7% +120 bps 44.5% 0% 30% 60% 16.2% +170 bps 14.5% FY 2014 FY 2015 Sales Q2 FY 2015 YoY Change YoY Change Excluding F
Slide 9: Cash Flow and Working Capital
9 Cash Flow and Working Capital(1) Operating Cash Flow 238$ 206$ CapEx (25) (35) Free Cash Flow 213$ 171$ Other Significant Sources/(Uses) of Cash: Dividends (63)$ (58)$ Notes Payable 300 135 Share Repurchase (304) (250) YTD FY15 YTD FY14 Dollars in millions (1) Figures include the impact of roundin
Slide 10: Pall's Exposure to Oil & Gas Production Market
10 Pall’s Exposure to Oil & Gas Production Market % of FY14 Revenue Revenue Exposure to Upstream and Midstream Oil & Gas Process Technologies 28% Low Microelectronics 11% None Aerospace 9% None BioPharm 36% None Food & Beverage 8% None Medical 8% None In du st ria l Li fe S cie nc es Revenue impac
Slide 11: Revenue by Currency
11 29% 29% 8% 6% 6% 22% 30% 27% 7% 6% 7% 23% Revenue by Currency FY14 Revenue by Currency Source for FX rates: Bloomberg Dollars in millions. Revenue by functional currency Other RMB GBP JPY USD EUR Approximately 70% of our sales are ex-US FY15 YTD Revenue by Currency Other RMB GBP JPY USD EUR
Slide 12: Current FX Rates vs. Original Plan
12 Current FX Rates vs. Original Plan 1.50 1.55 1.60 1.65 1.70 1.75 Aug-13 Oct-13 Jan-14 Apr-14 Jul-14 GBP / USD Recent FX Trends 1.10 1.20 1.30 1.40 1.50 Aug-13 Oct-13 Jan-14 Apr-14 Jul-14 EUR / USD CURR PLAN 1.35 1.54 95 105 115 125 Aug-13 Oct-13 Jan-14 Apr-14 Jul-14 USD / JPY CURR PLAN 102 FY15 F
Slide 13: Updated FY 2015 Outlook
13 Updated FY 2015 Outlook Original FY15 Plan (8/28/14) Q1 FY15 Update (11/25/14) (2) Current Update (2/24/15) (2) Pall Revenue Growth: Total Organic ex-Fx Mid-to-high single-digit Low-to-mid single-digit Low to mid single-digit Mid single-digit Low single-digit No change Segment Revenue
Slide 14: Updated FY 2015 Outlook (cont'd)
14 Updated FY 2015 Outlook (cont’d) Modeling Guidance Original FY15 Plan (8/28/14) Q1 FY15 Update (11/25/14) (2) Current Update (2/24/15) (1)(2) Gross Margin: 0 - 20 bps improvement No change No change SG&A: ~100 bps improvement No change ~70 – 100 bps improvement Operating Margin: ~100 bps improvem
Slide 15: Appendix
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2015 Pall Corporation Appendix
Slide 16: Appendix: Q2 Earnings and FY 2015 Estimates Reconciliation
16 Appendix: Q2 Earnings and FY 2015 Estimates Reconciliation of Non-GAAP Financial Measures Diluted EPS as reported 0.78$ 0.75$ 3.57$ Discrete Items: ROTC after pro forma tax effect 0.10 0.07 0.18 Total discrete items 0.10 0.07 0.18 Pro forma diluted EPS 0.88$ 0.82$ 3.75$ FY 2015 (Estimates at Midp
Slide 17: Appendix: Q2 Sales By Market & Technology Reconciliation
17 Appendix: Q2 Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q2 FY15 Q2 FY15 Estimated Impact of FX Q2 FY15 Estimate Excluding FX Q2 FY14 % Change Excluding FX Life Sciences Consumables Sales: BioPharmaceuticals 231,421$ (16,295)$ 247,716$ 218,625$ 13.3% Food & Beverage
Slide 18: Appendix: Q2 Orders by Segment Reconciliation
18 Appendix: Q2 Orders by Segment Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q2 FY15 Q2 FY15 Estimated Impact of FX Q2 FY15 Estimate Excluding FX Q2 FY14 % Change Excluding FX Life Sciences Orders: Consumables 374,364$ (27,846)$ 402,210$ 363,351$ 10.7% Systems 28,505 (1,864)
Slide 19: Appendix: Q2 Organic Sales Growth by Segment Reconciliation
19 Appendix: Q2 Organic Sales Growth by Segment Reconciliation of Non-GAAP Financial Measures Q2 FY15 Q2 FY14 Percent Change Q2 FY15 Impact of FX % Change Excluding FX Life Sciences Sales: Organic 345,699$ 353,230$ -2.1% (26,177)$ 5.3% Acquisitions 12,757 - - Total Life Sciences Sales 358,456$ 353,2
Slide 20: Appendix: Q2 Operating Profit Reconciliation
20 Appendix: Q2 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q2 FY15 Q2 FY14 Life Sciences segment profit 88,882$ 90,856$ Industrial segment profit 50,939 46,891 Total segment profit 139,821$ 137,747$ General corporate expenses (15,095) (14,766) Operating profit 12